The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of ...

J&J plans $55B US investment over 4 years, including 4 new factories. Construction begins on $2B NC biologics site, creating ...

Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for ...

President Donald Trump appears poised to bring back one of the drug pricing policies from his first term, as part of efforts ...

AstraZeneca invests $2.5B in China for vaccine plant & R&D facility, partners with BioKangtai, forms deals with Harbour ...

Chimerix began attracting deal interest in its experimental brain tumor treatment about 18 months before it signed a $935 ...

An annual gathering of industry and government officials focused on biomedical countermeasures and pandemic response has been ...

Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 ...

AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals ...

A meeting of CDC vaccine advisors that’s been in limbo for almost a month is slated to take place around the middle of April, ...

Brian Stephenson has stepped down after more than five years as CFO of BridgeBio, and president Tom Trimarchi will take over. Trimarchi was promoted to president and COO last ...

Visen Pharmaceuticals, a biotech developing much of Ascendis Pharma’s endocrine-related disease pipeline for the China market ...